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Abstract: Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder. Decreased platelet survival is the main
pathogenesis, which is related to platelet antibodies (APA). The levels of these antibodies are correlated with relapse and remission
which was shown for the first time by our group. Although APA levels decrease in remission they do not disappear as we have shown.
Among the several appraches to ITP treatment, oral megadose methylprednisolone is found to be the cheapest and most effective
one. For oral MDMP treatment, admission of the patients is not required and there is some evidence that chronic ITP could be
prevented by this approach.
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Introduction
Thrombocytopenias could be primary or secondary
(Table 1). Although secondary thrombocytopenias are
more common, idiopathic thrombocytopenic purpura
(ITP) is the most frequent among the primary
thrombcoytopenias.
Idiopathic thrombocytopenic purpura (ITP) is an
autoimmune disorder. Therefore, I would like to
emphasize that every autoimmune thrombocytopenic
purpura is not ITP (1). ITP abbreviation has also been
used for infectious thrombocytopenia in addition to
immune thrombocytopenia. Since their pathogenesis is
similar, idiopathic thrombocytopenic purpura should be
diagnosed by exclusion.
The diagnosis of ITP should be based on decreased
platelet counts (usually less than 50000/µl) with excessive
or normal megakaryocytes in the bone marrow.
Hepatosplenomegaly and lymphadenopathy should not be
detected and no recent history of drug ingestion including
aspirin, platelet or blood transfusions should be present.
In the mean time, underlying diseases such as lupus
erythemathosus, Coombs positivity (Evans syndrome),

hematologic malignancies, anti phospholipid antibodies,
thrombotic thrombocytopenic purpura and group A - β
hemolytic streptococcus infection should also be excluded
(2-4). If it is possible, antiplatelet antibodies (APA) should
be shown by Handin-Stossel (4,5) method as modified by
us (2).
When the thrombocytopenic period is shorter than 6
months those patients are accepted as acute ITP. If
thrombocytopenia persists for longer than 6 months
chronic thromocytopenia term is used.
Markedly shortened life-span of platelets in idiopatic
thrombocytopenic purpura during the thrombocytopenic
phase has repeatedly been demonstrated (6-10). This is
related to circulating antibodies first stongly suspected in
1951 and confirmed many times since then (11).
However the level of antiplatelet antibodies in relapse and
remission was not correlated until our studies (2-4,12).
Decreased platelet survival is essential in the
pathogenesis of ITP (6-10) which is improved with
remission but not normalized in most, if not all cases
(5,10,13), also as shown by us (2) (Table 2). We have
also shown the persistence of antiplatelet antibodies in
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Table 1. Causes of Thrombocytopenias.
I.Primary
A.Familial

a) Hereditary:
- autosomal dominant : May-Heyglin anomly, Sebastian (SBS), Fechtner (FS), Epstein (EPS), macrothrombocytopenia,
nephritis, deafness syndrome
- autosomal recessive (chronic thrombotic thrombocytopenic purpura (TTP), type II B von Willebrand disease
- X-linked : Wiscott-Aldrich syndrome
b) Non-hereditary: TAR syndrome, amegakaryocyte thromboctopenia, neonatal alloimmune thrombocytopenia, cyclic
thrombocytopenia
B) Non-familial: idiopathic thrombocytopenic purpura (ITP)
II-Secondary: due to a)
b)
c)
d)
e)
f)
h)
g)
k)
l)
m)

Viral infections
Sepsis
Drugs
DIC
Toxic (uremic etc)
Collagene disorders
Bone –marrow suppression
Leukemia and malignant disorders
Cyanotic heart disease
Alloimmune
Neonatal (septic. Viremic, etc)

Table 2. mean platelet survival in control subjects and ITP patients in remission: Pagocytosis of donor platelets by autologous leukocytes following
sensitization by the own sera indicated.
Age /sex
(yr)
13 /F
9 /F
15 /M
10 /M
15 /F
12 /M
Adult /
Adult /
Adult /
Adult /

Platelet
count (µl)

Platelet
life-span (days)

48000
52000

8.0
9.0
9.2
8.9
8.0
8.6

M
M
M
M

Chronic ITP cases in remission
15 /F
304000
15 /F
172000
12 /M
184000

11 /F
11 /M
11 /M
7 /M
9 /M
12/M
12/M
4/M
2,5/F
6/F
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8.6
2.8*
4.4

Acute ITP cases in remission
200000
7.4
172000
7.8
204000
2.0
1400000
3.0
172000
5.4
396 000
3
324000
2.1
236000
1.6
151000
368000

Phagocytosis of
Platelets (CPM)

Remarks

1.325
1.289
1.536
1.594
1699
1682

Normal
Normal
Normal
Normal
Aplastic anemia
Aplastic anemia
Blood donor
Blood donor
Normal
Normal

2.741
2.454

Splenectomized and inremission
2 yr
5 yr
6 yr

2.936
3.212
2.884
2134
2809
2244
2324
1986

Duration of remission
6 yr
3 yr
10 mo
> 1 yr
> 2 mos
> 3 mos
> 6 mos
> 4 mos
> 4 mos
> 7 mos
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remission for up to 6 years (2) . Platelet counts in relapse
and remission were well correlated with antiplatelet
antibody levels studied only by us, so far (4,12) (Figure
1-3).
This most likely indicates that normalization of
platelet counts in remission depends on compensatory
over production of platelets. This latter finding could be
important in the explanation of thrombocytopenia of
newborns whose mothers had had ITP in their childhood.
As a rule of thumb, treatment modalities should be
evaluated following the correct diagnosis and they should
be effective, economical, practical, applicable, ethical (and
ecological).

For the treatment of ITP, splenectomy, conventional
corticosteroid, cytoxan, iv vincristine, plasmaphoresis, vit
C, interferon, interleukin, cyclosporine, anti D serum, Fc
fragments of gammaglobulin, danazol, iv IgG (IVIG) and
megadose methylprednisolone (MDMP) have been used.
The presence of many alternatives for the treatment of a
disorder usually indicates that the ideal approach has not
yet been accepted by all researchers.
The necessity of treatment of acute ITP patients is
debatable, since its prognosis is very favorable, especially
in patients under 10 years of age. Some authors believe
that, with few exceptions, treatment is not required
(14,15), since platelet counts generally improve within a
few months without treatment (12).

0.150>
0.120
0.110
0.100
0.090
0.080

O.D

0.070
0.060
0.050
0.040
0.030
0.020
0.010
0.000
Controls

ThrombocRemission
ytopenic
ACUTE ITP

ThrombocRemission
ytopenic
CHRONIC ITP

Figure 1. Antiplatelet antibodies (APA) in acute and chronic ITP parients in thrombocytopenic
period and in remission.
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We have conducted an original study for the first and
so far only time for comparison of conventional oral
corticosteroid treatment with (iv) MDMP (13).

0.150>

0.120

Material and Methods

0.110

Forty-nine children with acute ITP who did not receive
any treatment previously, were the subject of the study.
Antiplatelet antibodies (4) (APA) were determined in all
patients just prior to treatment and right after platelet
counts reached >150000/µl. The diagnosis of acute ITP
was made in all 49 children according to the described
criteria above and thrombocytopenia was less than a
week duration.

0.100

0.090

O.D

0.080

The first case was chosen by chance (to the untreated
group) and the other patients were allocated to the other
groups successively. Platelets were enumerated by phase
contrast microscopy (18). Parents and the patients
themselves (older children) were comprehensively
informed about the disease, its complications and
prognosis. The patients were followed closely in the
hematology outpatient department.

0.070

0.060

0.050

0.040

Oral prednisone (2 mg/kg) was given once a day for 2
weeks, MDMP (iv) was administered in 5 to 10 minutes,
once a day (30 mg/kg daily for 3 d, 20 mg/kg for 4 d and
subsequently 10,5,2 and 1 mg/kg, for 1 week each)
before 9AM. A peripheral smear was obtained every 2nd
or 3 rd days. When platelets were seen on the smear,
counts were obtained and over 150000/µl was accepted
as an indication of success the treatment.

0.030

0.020

0.010

CONTROLS

0
Thrombocytopenic
Period

Remission

Figure 2. Antiplatelet antibody levels of 67 Children with acute ITP in
thromboytopenic Period with corresponding remission.

The main objective of any form of treatment should
be to raise the platelet counts rapidly in order to reduce
the risk of bleeding, especially intracranial hemorrhage.
Conventional corticosteroid was the drug of choice for
the treatment in chronic as well as acute ITP until 1985
when comparative oral corticosteroid, IVIG studies were
carried out. Despite similar results obtained in acute
childhood ITP treatment, in all rapid responders with
both approaches, IVIG has been suggested more often
despite its high cost and important side effects (16,17).
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Anemia (Hct<33%) was present in 2,7 and 3 patients
and leukocytosis (WBC>11000/µl) was found in 3,5 and
4 patients in the untreated, oral prednisone and MDMP
groups, respectively; the lowest Hct (16%) was in the
MDMP group and the highest WBC (16900/µl) was in the
untreated group.
Findings
In the first 2 weeks of the follow-up period,
spontaneous remission was observed in 5 (29.4%) of the
17 untreated children and in 5 (31.2%) of the 16
patients who had been treated with oral prednisone.
Platelet counts were above 150000/µl in 11 of 16
patients in the MDMP treatment group on the 3 rd day of
administration. In 2 more patients this elevation was
observed on the 5 th day and in another 2 on the 14 th
day of treatment.

fi. ÖZSOYLU

0.150

0.120

O.D

0.090

0.060

0.030

0.000
Thrombocytopenic

Remission

Relaps

Remission

ACUTE ITP
CHRONIC ITP

Figure 3. Anteplatelet antibody levels of 21 children with chronic ITP and 2 patients
with acute ITP in thrombocytopenic period and in remission are shown. Relas
APA values of 4 chronic ITP patinets with their reremission determinations in
2 of them are indicated. Relaps APA values of 2 acute ITP are also included.

In the 4 th week, the platelet count was over
150000/µl in 12 (70.6%) of the 17 untreated patients,
in 7 (43.7%) of the 16 patients who had been given oral
prednisone for 2 weeks, and in all 16 (100%) of the
group treated with MDMP. When the results were
evaluated by the chi-square test, significantly better
improvement was found only in the MDMP group (P <
0.01 for the 1st and 2 nd week and P < 0.05 for the 4
th week. No significant differences were observed
between the untreated and orally treated groups (P >
0.05 at each evaluation) (Table 3).
Initial APAs, indicated as optical density reading over
0.030 at 580 nm, were 0.107 ± 0.044 (X ± S.D., range:
0.46-0.211) in the oral prednisone treated group

0.108±0.038 (range:0:060-0.219) in the untreated
group and 0.115±0.035 (range 0.060-0.200) in the
MDMP group; there were no significant differences
between them. Following normalization of platelet count,
the antibodies were decreased but could still be detected
in every case (Figure 4). They were found to be below
0.030 in all 126 normal and thrombocytopenic control
sera (4).
The early platelet response was also observed in most
of the 6 patients unresponsive to oral prednisone who
were treated 4 months later with MDMP (Table 3).
Decrease of APA, could be determined in 4 of these 6
children in whom platelet counts were normalized as seen
in (Figure 4).
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Table 3. Age, sex, and time to remission in 3 groups of children with acute ITP treated with MDMP, oral
prednisone, or untreated.

No.of patients
Mean age (range) in months
Male: Female
No.of patients in remission*:
3rd day treatment
1st week treatment
2nd week treatment
4th week treatment
Up to 4 months

MDMP

oral prednisone
(2 mg/kg)

Untreated

16
46(3-156)
11:5

16
64.5 (19-132)
10:6

17
77.5 (19-156)
7:10

11(68.7%)
13 (81.2%)
15 (93.7%)
16 (100%)

3 (18.7%)
5 (31.5%)
7(43.7%)
7+2 (partial)**

2 (11.7%)
5(29.4%)
12 (70.6%)
14+1 (partial)

* Plt count 150/µl
** Partial remission: 150.000/µl > plt > 100000/µl
ÖZSOYLU et al. Eur J Haematol 1989;42:431-435

Table 4. Age, sex and days of platelet response to MDMP in children unresponsive to oral
prednisone (2mg/kg).
No. of patients
Mean age (range) in months
Male: Female
No.of patients in remission:*
3rd day
1 week
Unresponsive
Number of patients relapsed

6
72 (48-84)
4/2
3+1 (partial)**
5 (83.5%)
1
2(2 and 6 months later)

and ** as in Table 2
ÖZSOYLU et al. Eur J Haematol 1989: 42:431-435

Discussion
The improvement of platelet counts which occurred
within 4 weeks in about 70.6%, and in 88% of these
children by the end of 4 months would support the
concept that treatment of ITP in children may not be
mandatory if bleeding is not a problem; however, such a
prediction is not possible.
Our results definitely show that MDMP treatment is
much superior to conventional treatment as well as to
non treatment. To our surprise, the platelet response of
the untreated group seemed better than the conventional
treatment group although it was not statistically
significant.
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Decrease of APA was shown in each case in our study
following normalization of platelet counts. The antibodies
in 4 of the patients unresponsive to oral prednisone were
also found to decrease following normalization of platelet
count with MDMP treatment. These determinations could
not be performed in 2 patients. One was unresponsive,
and posttreatment sera could not be obtained from the
other. Although antiplatelet antibodies decreased
following remission in all patients; more markedly in
MDMP administered group (Figure 4), in they were
detectable in each case.
Although remission was observed 70.6% of the
untreated and 43.7 % of conventionally treated group at
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0.20

0.15

0.10

0.05
0.03

a
b
Oral pred

a
b
Untreated

a

b
MDMP

MDMP
after oral Pred

Figure 4. Initial (a) and improvement (b) antiplatelet antibodies of the patients are shown.

4 weeks of follow up period, 68.7% early response at 3
rd day was observed only in patients treated with MDMP.
Early elevation of platelet counts, important for families
and patients psychologically as well as prevention of
bleeding, is expected more in the early days of ITP.

Therefore we advise 7 days oral dose regimen for the
present, each dose being given around 6 AM. We have
also compared IVIG (2 g/kg dose) results with our oral
MDMP administration which were found comparable (20)
(Table 7).

Although response to MDMP treatment was better
than conventional corticosteroid treatment, about 35
days of iv administration methylprednisolone period
seemed to be too long for a disorder with good
prognosis. Since platelet counts were elevated over
150000/µl within a week of the treatment in more than
81% of the patients, we used 7 days (30mg/kg for days
then 20 mg/kg for 4 days) treatment. Later these doses
were given orally and compared with iv treatment and
were found not different from each other (19) (Table 5).
Since response to iv MDMP was 68.7% in 3 days, oral
MDMP (30 mg/kg) for 3 days treatment, was compared
one week (30 mg/kg days then 20 mg/kg for 4 days)
MDMP administration. Each oral dose was given at once
around 6 AM when blood corticosteroid level was with
highest physiologically. Although platelet response
(>150000/µl) within a week was comparable, recurrence
within 4 weeks were observed in 50% of the cases who
were given 3 days treatment but in 12.5% with 7 days
administration (Table 6).

Chronicity was observed in 4 of 59 (6.8%) patients
with acute ITP treated with MDMP and in 13 (12.3%)
out of 105 (who could be followed out of 118 patients)
treated with conventional corticosteroid (P < 0.05). If
this is documented in more patients with acute ITP,
MDMP administration would have another advantage of
prevention of chronic ITP.
We have used iv MDMP in the treatment of chronic
ITP cases, earlier than its administration for acute ITP
patients (21,22). The same dose of methylprednisolone
(30mg/kg for 3 days, then 20 mg/kg for 4 days, followed
by 10,5,2 and 1 mg/kg dose for one week, each dose
given before 9 AM in 5 to 10 minutes) was given as in
treatment of acute ITP cases. The results of 29 patients
with chronic ITP were reported in 1984 by us21. The
results, 14 of more cases with this disorder, were added
to initial findings for the evaluation of the responses (22)
(Table 8). If platelet response remained under 100
000/µl during 35 days of treatment or after, those cases
were accepted as none-responsive. If platelet count
353
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Table 5. Oral versus iv MDMP for acute ITP cases (7 days; 30 mg/kg for 3 days, then 20 mg/kg
for 4 days).
Oral

iv

Patients (n)

15

16

Mean age (range mos)

59.6 (1-132)

64.8(1-166)

Male / female

9/6

6/10

Patients in remission over 2 weeks

13 (86.7%)

12 (75.4%)

Table 6. Three days versus 7 days MDMP treatment.
3 days
(30 mg/kg/dl)

7 days
(30mg/kg 3 days; + 20 mg/kg 4 days)

Remission in one week

6/7 (85.7 %)

7/9 (77.8%)

Relaps within 4 weeks

3 (50%)

1 (12.5%)

Table 7. (Age, sex, ahr early response rates to treatment of patients with their 6 months follow-up).
Oral MDMP 7 days
(30 mg/kg 3 days+20 mg/kg 4 days)

IVIG
(0.4g/kg for 5 days)

No of patient

10

10

Mean age (range in months)

69.8(2-108)

60.5(2-132)

Male/female

6/4

5/5

No of patients in complete remission (plt count≥150 000/µl

n(%)

n (%)

3rd day treatment

6/10 (60%)

6/10 (60%)

7th day

8/10 (80%)

9/10 (90%)

4th week

7/10 (70%)

6/10 (60%)

3rd month

7/10 (70(%)

6/8 (75%)

6 th month

9/10 (90%)

6/8 (75%)

During follow-up

Özsoylu fi, et al. Pediatr Hematol /Oncol 1993;10:317-321

Table 8. MDMP for chronic ITP patient.
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girls (n:18)

boys (n:25)

total (n:43)

Sustained response

3(16.7 %)

13(36%)

16(37.2%)

Non-persistent resp.

11(61.1%)

9(36%)

20(46.5%)

Unresponsive

4(22.2%)

3 (12%)

7 (16.3%)

fi. ÖZSOYLU

increased 150 000/µl and remained there sustained
response, and if platelet count raised over 100000/µl
during treatment but decreased later, nonpersistent
response were considered. By this response score only
16.3 % (7 of 43 plt) of the patients were found non
responsive, 83.2% responsive; 37.2% (16 pts) were
sustained responsive, and 46.5 % (20 pts) were non persistent responsive (22).
Since response was mostly observed in 2 weeks of
treatment, later patients with chronic ITP were treated
by oral MDMP (30 mg/kg for 1 week then 20 mg/kg
another week). Each dose was given 6 AM at once. In
obtaining sustained response, more than one cure of
MDMP was required in some cases and 4 cures were
necessary for one patient. More than one cure of the
treatment were used for those patients who were
bleeding with chronic thrombocytopenia, and the
response rate was found comparable to iv MDMP.
MDMP treatment has also been used in adult chronic
ITP patients with success (23,24).
Because methylprednisolone taste extremely bitter,
each daily oral dose (as powder) was put on a tablespoon
and was covered by honey so that patients could take it.
A glass of milk was given afterwards, as in treatment of
acute ITP cases.
Saline nose drops was administered to all patients
when MDMP was given, as described by us (25).
The major side effect of the treatment was abdominal
disomfort, which was observed in at least half of the
patients; was but not severe enough to discontinue
MDMP administration in any of them. Mild Cushingoid
appearance was observed in more than one tenth of the
patients with long term (35 days) administration, but
rarely with one or two weeks treatment. Other
corticosteroid
effects
such
as
hypertension,
hyperglycemia, glycosuria and corneal opacities were not
seen in patients treated with MDMP for acute or chronic
ITP cases as confirmed by others (26). A 13 year old girl
with acquired aplastic anemia had developed diabetes due
to deltacortril and testosterone treatment, before being
referred to us and was then treated with MDMP. Her
steroid induced diabetes as well as aplastic anemia was
completely cured even though she was insulin dependent
prior to MDMP treatment (27).
So far, more than 400 patients with different diagnosis
have bean treated with MDMP for much longer period

than ITP cases (28-30). Cataract was diagnosed in three of
them, two of whom were operated an and one patient
with Diamond-Blackfan anemia (congenital pure red cell
anemia). Oral moniliasis was observed in 2 patients who
used MDMP for a long period of time and was treated by
local sodium bicarbonate (1%) administration. All patients
used saline nose drops prophylactically at least 3 times a
day (25). No serious infections was seen in any of our
patients with acute or chronic ITP.
With MDMP administration, erythropoietin (EPO)
granuclocyte macrophage colony stimulating factor
(GCSF) elevation and some lymphocyte subsetts increase
have been shown (31,32). The cost of
methylprednisolone is one sixtieth of the IVIG (2 g/kg)
price for acute ITP patients. Since oral MDMP is
administered at home and hospital admission is advised,
for IVIG treatment the cost would be much more than
oral MDMP treatment for acute ITP.
From these experiences it could be concluded that:
a. Antiplatelet antibodies which are IgG fraction, are
present in all acute and chronc ITP cases,
b. These antibodies could also be shown in all cases
during remission, though they are lower,
c. Mean platelet survival is shorter not only in
relapse but in remission in most of the cases.
d. Therefore, normal platelet counts in remission
should be due to compensatory over production of
platelets.
e. If treatment of acute ITP is required, MDMP is the
most effective and cheapest approach.
f. With MDMP treatment, APA levels decreased most
efficiently, during remission
g. Chronicity of acute ITP would probably be less
with MDMP treatment
h. Oral MDMP treatment is more convenient and
cheaper than other effective treatments.
Patient admission is not necessary for MDMP
administration which makes it more cost effective.
Corresponding author:
fiinasi ÖZSOYLU
Beysukent, Altınflehir Sitesi, No: 30,
Ankara - Turkey
E-mail: sinasiozsoylu@hotmail.com
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